Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | PDE6D | O43924 | 1/20 | 0.49 |
| ▸ | PDE6A | P16499 | 1/20 | 0.49 |
| ▸ | PDE6G | P18545 | 1/20 | 0.49 |
| ▸ | PDE6B | P35913 | 1/20 | 0.49 |
| ▸ | PDE6C | P51160 | 1/20 | 0.49 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430575 | 0.90 | THRB (0.61) | PDE5ATHRBPDE6DPDE6APDE6G | |
| SCHEMBL1983100 | 0.89 | MAPK1 (0.48) | PDE5AKDM4EL3MBTL1MAPTGAA | |
| SCHEMBL441445 | 0.87 | PDE5A (0.55) | PDE5ATHRBPDE6DPDE6APDE6G | |
| SCHEMBL649687 | 0.87 | PDE5A (0.60) | PDE5ATHRBPDE6DPDE6APDE6G | |
| SCHEMBL6197990 | 0.84 | TP53 (0.63) | KDM4EL3MBTL1MAPTGAANPSR1 | |
| SCHEMBL4428236 | 0.84 | PDE5A (0.56) | PDE5ATHRBPDE6DPDE6APDE6G | |
| SCHEMBL538115 | 0.84 | NMT1 (0.61) | KDM4EL3MBTL1MAPTGAANPSR1 | |
| SCHEMBL1467161 | 0.83 | MAPK1 (0.65) | KDM4EL3MBTL1MAPTGAANPSR1 | |
| SCHEMBL6200293 | 0.83 | MAPK1 (0.55) | KDM4EL3MBTL1MAPTGAANPSR1 | |
| SCHEMBL4352879 | 0.83 | MAPT (0.65) | PDE5ATHRBL3MBTL1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114751858-B | Quinolinyl-containing tranexamic acid derivative and preparation and application thereof | 沈阳药科大学 | 2023-09-12 | — | — | CN | disclosed |
| CN-114751858-A | Quinolinyl-containing tranexamic acid derivative, preparation and application thereof | 沈阳药科大学 | 2022-07-15 | — | — | CN | disclosed |
| EP-2164328-B1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | DART NEUROSCIENCE CAYMAN LTD (KY) | 2013-08-07 | — | — | EP | disclosed |
| US-8343957-B2 | Therapeutic pyrazoloquinoline urea derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-01-01 | — | — | US | disclosed |
| US-8343957-B2 | Therapeutic pyrazoloquinoline urea derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-01-01 | — | — | US | disclosed |
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7884113-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080306048-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306048-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306048-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-14 | — | — | US | disclosed |
| EP-1644335-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-04 | — | — | EP | disclosed |
| EP-1644335-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005007628-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-20 | — | — | US | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
| US-4450166-A | N-(4,5-Dihydro-thiazol-2-yl)-3-quinoline-carboxamides having anxiolytic activity | ROUSSEL UCLAF (FR) | 1984-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | PDE5A 1747/4885THRB 809/4885PDE6D 2760/4885 |
| US-20080306048-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | GABRB1, GABRA5, GABRB2 | PDE5A 198/4885THRB 501/4885PDE6D 1808/4885 |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | GABRB1, GABRA5, GABRB2 | PDE5A 198/4885THRB 501/4885PDE6D 1808/4885 |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | PDE5A 1747/4885THRB 809/4885PDE6D 2760/4885 |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | PDE5A 1747/4885THRB 809/4885PDE6D 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.